Statins: a treatment option for chronic heart failure?

Stephan von Haehling, Darlington O. Okonko, Stefan D. Anker

Research output: Contribution to journalArticle

Abstract

Statins, also known as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, consistently reduce cardiovascular risk. It has recently emerged that cholesterol reduction is not their only mode of action, with current research largely focused on the pleiotropic effects of statins. These include the improvement of endothelial dysfunction, their anti-inflammatory properties, and the mobilization of bone marrow-derived endothelial progenitor cells. All these effects are potentially beneficial in chronic heart failure (CHF), although prospective trials are needed to confirm this. However, cholesterol reduction by statins per se may prove detrimental in patients with CHF, as cholesterol seems to be able to inactivate endotoxin as a stimulus for proinflammatory cytokine production. It is therefore tempting to speculate that low doses of statins still confer pleiotropic effects without lowering plasma cholesterol levels.

Original languageEnglish
Pages (from-to)90-97
Number of pages8
JournalHeart failure monitor
Volume4
Issue number3
Publication statusPublished - 2004

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Heart Failure
Cholesterol
Therapeutics
Endotoxins
Oxidoreductases
Anti-Inflammatory Agents
Bone Marrow
Cytokines
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

von Haehling, S., Okonko, D. O., & Anker, S. D. (2004). Statins: a treatment option for chronic heart failure? Heart failure monitor, 4(3), 90-97.

Statins : a treatment option for chronic heart failure? / von Haehling, Stephan; Okonko, Darlington O.; Anker, Stefan D.

In: Heart failure monitor, Vol. 4, No. 3, 2004, p. 90-97.

Research output: Contribution to journalArticle

von Haehling, S, Okonko, DO & Anker, SD 2004, 'Statins: a treatment option for chronic heart failure?', Heart failure monitor, vol. 4, no. 3, pp. 90-97.
von Haehling S, Okonko DO, Anker SD. Statins: a treatment option for chronic heart failure? Heart failure monitor. 2004;4(3):90-97.
von Haehling, Stephan ; Okonko, Darlington O. ; Anker, Stefan D. / Statins : a treatment option for chronic heart failure?. In: Heart failure monitor. 2004 ; Vol. 4, No. 3. pp. 90-97.
@article{fa31d0f6433f412d82f692a3340e8f7f,
title = "Statins: a treatment option for chronic heart failure?",
abstract = "Statins, also known as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, consistently reduce cardiovascular risk. It has recently emerged that cholesterol reduction is not their only mode of action, with current research largely focused on the pleiotropic effects of statins. These include the improvement of endothelial dysfunction, their anti-inflammatory properties, and the mobilization of bone marrow-derived endothelial progenitor cells. All these effects are potentially beneficial in chronic heart failure (CHF), although prospective trials are needed to confirm this. However, cholesterol reduction by statins per se may prove detrimental in patients with CHF, as cholesterol seems to be able to inactivate endotoxin as a stimulus for proinflammatory cytokine production. It is therefore tempting to speculate that low doses of statins still confer pleiotropic effects without lowering plasma cholesterol levels.",
author = "{von Haehling}, Stephan and Okonko, {Darlington O.} and Anker, {Stefan D.}",
year = "2004",
language = "English",
volume = "4",
pages = "90--97",
journal = "Heart failure monitor",
issn = "1470-8590",
publisher = "Remedica Publishing Ltd.",
number = "3",

}

TY - JOUR

T1 - Statins

T2 - a treatment option for chronic heart failure?

AU - von Haehling, Stephan

AU - Okonko, Darlington O.

AU - Anker, Stefan D.

PY - 2004

Y1 - 2004

N2 - Statins, also known as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, consistently reduce cardiovascular risk. It has recently emerged that cholesterol reduction is not their only mode of action, with current research largely focused on the pleiotropic effects of statins. These include the improvement of endothelial dysfunction, their anti-inflammatory properties, and the mobilization of bone marrow-derived endothelial progenitor cells. All these effects are potentially beneficial in chronic heart failure (CHF), although prospective trials are needed to confirm this. However, cholesterol reduction by statins per se may prove detrimental in patients with CHF, as cholesterol seems to be able to inactivate endotoxin as a stimulus for proinflammatory cytokine production. It is therefore tempting to speculate that low doses of statins still confer pleiotropic effects without lowering plasma cholesterol levels.

AB - Statins, also known as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, consistently reduce cardiovascular risk. It has recently emerged that cholesterol reduction is not their only mode of action, with current research largely focused on the pleiotropic effects of statins. These include the improvement of endothelial dysfunction, their anti-inflammatory properties, and the mobilization of bone marrow-derived endothelial progenitor cells. All these effects are potentially beneficial in chronic heart failure (CHF), although prospective trials are needed to confirm this. However, cholesterol reduction by statins per se may prove detrimental in patients with CHF, as cholesterol seems to be able to inactivate endotoxin as a stimulus for proinflammatory cytokine production. It is therefore tempting to speculate that low doses of statins still confer pleiotropic effects without lowering plasma cholesterol levels.

UR - http://www.scopus.com/inward/record.url?scp=17844386405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844386405&partnerID=8YFLogxK

M3 - Article

C2 - 15772704

AN - SCOPUS:17844386405

VL - 4

SP - 90

EP - 97

JO - Heart failure monitor

JF - Heart failure monitor

SN - 1470-8590

IS - 3

ER -